ariah.bio’s team revolutionizes the understanding of human tissue complexity using a combined expertise of multiplex imaging and AI computational tools.
They explore cellular distributions and decode tissue microenvironments to reveal the unseen.

ariah.bio provides a specialized expertise and tailored solutions in biomarker identification, group stratification and efficacy evaluation using Spatial Biology and multiplex imaging analysis.

The company is paving the way for a new generation of multiplex imaging diagnostic tests.

Skinosive is a science-based biotechnology company specializing in dermocosmetics, founded by Truffle Capital, which is developing a proprietary technology platform called “bioadhesion” that could be applied to several use (cosmetic, medical…)

Skin cancer is the leading cause of cancer among Caucasians. The best means of prevention remains sun protection, but this has two major limitations: its effectiveness, as it must be reapplied every two hours, and the issue of skin penetration.

Skinosive is the only company developing an innovation based on a new generation of safe, long-acting bioadhesive filters. This breakthrough represents a radical innovation in sun protection and skin cancer prevention.

Skionosive’s mission is to revolutionize sun protection through a unique biotechnology platform. Molecules develop will stick to the skin, do not need to reapply every 2 hours, allow an extended duration of effectiveness up to 8 hours and does not penetrate the skin.

Their proprietary bio-adhesive technology is designed to set a new standard in sun protection. Their approach involves developing new UV filters that combine a bio-adhesive complex with already-approved UV filters, enabling them to anchor themselves to the stratum corneum, thereby improving durability with proven efficacy for up to 8 hours and limiting skin penetration.

The company is based in France, with headquarters in Paris and laboratories in Marseille.

Biomunex Pharmaceuticals is a Paris- and Cambridge-based biopharmaceutical company developing innovative immunotherapies to address unmet medical needs in oncology. The company leverages its proprietary BiXAb® platform, next-generation technologies enabling the rapid and cost-effective generation of bi- and multi-specific antibodies from any pair of monoclonals.

BiXAb® has been validated through strategic collaborations with Ipsen with a major licensing agreement worth up to $610M, but also with Sanofi and Onward Therapeutics.

Biomunex is pioneering MAIT engagers, a novel class of bispecific antibodies designed to mobilize MAIT cells to selectively eliminate tumor cells, and destroy solid tumors. This approach has the potential to improve safety and efficacy compared to existing T cell engagers.

With a strong pipeline, including clinical-stage assets, Biomunex aims to advance disruptive therapies while establishing strategic partnerships and securing additional funding to accelerate development.